26 studies found for:    poly iclc | Open Studies
Show Display Options
Rank Status Study
1 Recruiting Enhancement by Poly-ICLC During HIV-1 Infection
Condition: HIV-1 Infected Adults With Chronic HIV-1 Infection
Interventions: Drug: Arm A: Poly-ICLC;   Drug: Arm B: Normal Saline
2 Recruiting A Trial of Poly-ICLC in the Management of Recurrent Pediatric Low Grade Gliomas
Condition: Brain Tumors
Intervention: Drug: Poly ICLC
3 Recruiting In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®
Conditions: Melanoma;   Head and Neck Cancer;   Sarcoma;   Non-Melanoma Skin Cancers
Intervention: Biological: Hiltonol
4 Recruiting In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
Condition: Low-Grade B-cell Lymphoma
Interventions: Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
5 Recruiting Phase I/II Trial of IMA950 Multi-peptide Vaccine Plus Poly-ICLC in Glioblastoma
Condition: CNS Tumor, Adult
Interventions: Biological: IMA 950;   Biological: Poly ICLC;   Other: Immunomonitoring
6 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, and IDO1 Inhibitor INCB024360 in Treating Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Remission
Conditions: Fallopian Tube Carcinoma;   Ovarian Carcinoma;   Primary Peritoneal Carcinoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Poly ICLC;   Drug: IDO1 Inhibitor INCB024360;   Other: Pharmacological Study;   Other: Laboratory Biomarker Analysis
7 Recruiting Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies
Condition: Melanoma
Interventions: Biological: pBCAR3-phosphopeptide;   Biological: pIRS2-phosphopeptide;   Biological: 2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)
8 Recruiting Pilot Study of a Breast Cancer Vaccine Plus Poly-ICLC for Breast Cancer
Condition: Breast Cancer
Intervention: Biological: 9 Peptides from Her-2/neu, CEA, & CTA + poly-ICLC
9 Recruiting A Pilot Study of Glioma Associated Antigen Vaccines in Conjunction With Poly-ICLC in Pediatric Gliomas
Conditions: Newly Diagnosed Pediatric Pontine Glioma.;   Newly Diagnosed Pediatric High Grade Glioma.;   Recurrent Pediatric High Grade Glioma.;   Recurrent Pediatric Low Grade Glioma.
Interventions: Biological: HLA-A2 restricted glioma antigen peptides vaccine;   Biological: Poly-ICLC
10 Recruiting CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma
Conditions: Carcinoma of Unknown Primary Origin;   Iris Melanoma;   Medium/Large Size Posterior Uveal Melanoma;   Mucosal Melanoma;   Ocular Melanoma With Extraocular Extension;   Small Size Posterior Uveal Melanoma;   Stage IIB Skin Melanoma;   Stage IIB Uveal Melanoma;   Stage IIC Skin Melanoma;   Stage IIIA Skin Melanoma;   Stage IIIA Uveal Melanoma;   Stage IIIB Skin Melanoma;   Stage IIIB Uveal Melanoma;   Stage IIIC Skin Melanoma;   Stage IIIC Uveal Melanoma;   Stage IV Skin Melanoma;   Stage IV Uveal Melanoma
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Other: Laboratory Biomarker Analysis;   Biological: Neoantigen-based Melanoma-Poly-ICLC Vaccine;   Other: Pharmacological Study;   Biological: Recombinant Flt3 Ligand
11 Recruiting A Vaccine Trial for Low Grade Gliomas
Condition: Low Grade Glioma
Intervention: Biological: Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC
12 Not yet recruiting Safety Study of a Helper Peptide Vaccine Plus Adjuvant Combinations for the Treatment of Melanoma
Condition: Melanoma
Interventions: Biological: 6MHP;   Drug: Montanide ISA-51;   Drug: polyICLC;   Drug: Cyclophosphamide
13 Recruiting Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission
Conditions: Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions: Biological: basiliximab;   Biological: WT1 126-134 peptide vaccine;   Drug: Montanide ISA 51 VG;   Drug: poly ICLC;   Other: laboratory biomarker analysis
14 Recruiting Phase II Study With Hiltonol and Dendritic Cells in Solid Tumors
Condition: Neoplasms
Intervention: Biological: Hiltonol and autologous dendritic cells
15 Recruiting Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma
Condition: Cutaneous T-cell Lymphoma
Interventions: Drug: Romidepsin;   Drug: Poly ICLC;   Radiation: Focal lesional radiation
16 Not yet recruiting A Comparison of Matured Dendritic Cells and Montanide® in Study Subjects With High Risk of Melanoma Recurrence
Condition: Melanoma
Interventions: Biological: DC Vaccine;   Biological: Montanide Vaccine;   Biological: Poly-ICLC
17 Recruiting GAPVAC Phase I Trial in Newly Diagnosed Glioblastoma Patients
Condition: Glioblastoma
Interventions: Drug: APVAC1 vaccine plus Poly-ICLC and GM-CSF;   Drug: APVAC2 vaccine plus Poly-ICLC and GM-CSF
18 Recruiting DEC-205/NY-ESO-1 Fusion Protein CDX-1401and Decitabine in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia
Conditions: Acute Myeloid Leukemia;   Alkylating Agent-Related Acute Myeloid Leukemia;   Chronic Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Refractory Anemia With Excess Blasts in Transformation
Interventions: Biological: DEC-205/NY-ESO-1 Fusion Protein CDX-1401;   Drug: Poly ICLC;   Drug: Decitabine;   Other: Laboratory Biomarker Analysis
19 Recruiting Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists
Conditions: Melanoma;   Metastatic Melanoma;   Mucosal Melanoma
Interventions: Biological: Peptide Vaccine (LPV7) + Tetanus peptide;   Other: PolyICLC;   Other: Resiquimod;   Other: IFA
20 Recruiting A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma
Condition: Unresectable Stage III or Stage IV Melanoma
Interventions: Drug: Combination of varlilumab and ipilimumab;   Drug: Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC

   Previous Page Studies Shown (1-20) Next Page (21-26) Show next page of results    Last Page
Indicates status has not been verified in more than two years